Akeso Receives FDA Approval For Penpulimab-kcqx To Treat Advanced Nasopharyngeal Carcinoma
25/4 03:01
(RTTNews) - Akeso Inc. announced that the U.S. Food and Drug Administration has approved its differentiated PD-1 monoclonal antibody, penpulimab-kcqx, in combination with cisplatin or carboplatin and gemcitabine for the first-line treatment of adult recurrent or metastatic non-ke...